29th - 30th October, 2020

4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress (Time Zone - GREENWHICH MEAN TIME(GMT))

In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.

  • 30+ experts from academia and industry will be presenting their current work in Immuno-Oncology, Latest updates on regulatory guidelines and approvals, Validation markers for tumor-derived T-cell subpopulations, NextGen T-Cell and CAR-T Cell therapy, Personalized Medicine, Biomarkers and Cancer Immunotherapy
  • Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.
  • Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, Validation methods and innovative tools in IO Discovery, Oral T-Cell Therapies for the Treatment of Cancer Patients and Discovery of novel bispecific antibody molecules to boost anti-tumor immunity

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th March 2020 in London, UK would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

CONFERENCE SPEAKERS

Advisors
Stefan Glueck
Stefan Glueck
Ex- Vice President, Global Head Franchise Oncology
Regeneron
Sophia Karagiannis
Sophia Karagiannis
Professor, Translational Cancer Immunology and Immunotherapy
Kings College London, UK
Speakers
Roy Baynes
Roy Baynes
Senior Vice President and Head Global Clinical Development, Chief Medical Officer
Merck Research Laboratories
Bruno Tullia
Bruno Tullia
Assistant Professor, Immunology
University of Pittsburgh
Illip Burmester, Ph.D.
Illip Burmester, Ph.D.
Scientific Sales Support Europe
Proteome Sciences
David Gilham
David Gilham
Vice President, R&D
Celyad, UK
John Maher
John Maher
Scientific Founder and Chief Scientific Officer
Leucid Bio
Sheeba Irshad
Sheeba Irshad
CRUK Clinician Scientist & Honorary Medical Oncologist
Guys Hospital, UK
Will Arends
Will Arends
Chartered (UK) and European Patent Attorney
Marks & Clerk, UK
Markus Zettl
Markus Zettl
Director, Immuno-Oncology
Pieris Pharmaceuticals, Germany
Renier Heijkants
Renier Heijkants
Senior Scientist
APO-T
Sam Shrivastava
Sam Shrivastava
Chief Executive Officer, Founder
Venn Therapeutics
Justyna Rzepecka
Justyna Rzepecka
Principal Scientist Immunology
Concept Lifesciences
Colin Self
Colin Self
CEO
Precision Therapeutics
Bradlee Heckmann
Bradlee Heckmann
CSO
Asha Therapeutics
Manish	Kumar
Manish Kumar
Product Manager Cells and Media
PromoCell
Marsilio Adriani
Marsilio Adriani
Principal Scientist
4D Pharma
Soldano Ferrone
Soldano Ferrone
Professor
Harvard University, USA
Stefan Glueck
Stefan Glueck
Ex- Vice President, Global Head Franchise Oncology
Regeneron
Stephen Harper
Stephen Harper
Group Leader, Protein Science
Immunocore, UK
Sophia Karagiannis
Sophia Karagiannis
Professor, Translational Cancer Immunology and Immunotherapy
Kings College London, UK
Angela Vasaturo
Angela Vasaturo
Senior Field Application Scientist
Ultivue, UK
Ann White
Ann White
Senior Principal Scientist
UCB Celltech, UK
Aude De Gassart
Aude De Gassart
Director of Preclinical Research
ImCheck Therapeutics, France
Ali Roghanian
Ali Roghanian
Assistant Professor, Cancer Immunology
University of Southampton, UK
Lindy Durrant
Lindy Durrant
Professor, Cancer Immunotherapy
University of Nottingham, UK
Deyarina Gonzalez
Deyarina Gonzalez
Professor, Molecular Medicine
Swansea University Medical School, UK
Audrey Gerard
Audrey Gerard
KTRR Senior Research Fellow
University of Oxford, UK
Marcello Stein
Marcello Stein
Global Product Manager, T Cell Immunology
Miltenyi Biotec, Germany
Maik Pruess PhD
Maik Pruess PhD
Senior Field Application Scientist
Personalis Inc
Rorn Korn
Rorn Korn
Founder, Chief Medical Officer
Imaging Endpoints, USA
Victoria Sanz-Moreno
Victoria Sanz-Moreno
Professor, Cancer Cell Biology
Cancer Research UK Barts Centre, UK
Archie Wall
Archie Wall
PhD Researcher
University College London, UK
Ben Xu
Ben Xu
BD Director, Biologics Development
GenScript, USA
Mustapha Faroudi
Mustapha Faroudi
Director of Immuno Oncology,
Biomunex Pharmaceuticals
Idhnan Hussain
Idhnan Hussain
Flow Cytometry Technical Specialist
Thermo Fischer Scientific, UK
Steven Lynum
Steven Lynum
Executive Director, Global Business Development
PHC Corporation, USA
Jennifer Freeland
Jennifer Freeland
Global Market Development Manager, Immunohistochemistry
EPREDIA
Grace Robinson
Grace Robinson
Global Market Development Manager Archiving
EPREDIA
James Watson
James Watson
Senior Business Development Manager
Thermo Fischer Scientific, UK
Nicola McCarthy
Nicola McCarthy
Global Scientific Liaison
Horizon Discovery, UK
Eden Kleiman
Eden Kleiman
Senior Scientist Immuno-oncology
CrownBio

SPONSORS